Abstract
Age-related neurodegeneration in the brain and retina is complicated. It comprises a series of events encompassing different modes of degeneration in neurons, as well as inflammation mediated by glial cells. Systemic inflammation and risk factors can contribute to disease progression. Age-related conditions such as Alzheimers disease (AD), Parkinsons disease (PD) and Age-related Macular Degeneration (AMD) affect patients for 5 to 20 years and are highly associated with risk factors such as hyperhomocysteinæmia, hypercholesterolæmia, hypertension, and symptoms of mood disorder. The long duration of the degeneration and the wide array of systemic factors provide the opportunity for nutraceutical intervention to prevent or delay disease progression.
Small molecules such as phenolic compounds are candidates for neuroprotection because they have anti-oxidant activities and can modulate intracellular signaling pathways. Bigger entities such as oligosaccharides and polysaccharides have often been neglected because of their complex structure. However, certain big molecules can provide neuroprotective effects. They may also have a wide spectrum of action against risk factors.
In this review we use an integrative approach to the potential uses of nutraceutical products to prevent age-related neurodegeneration. These include direct effects of phenolic compounds and polysaccharides on neurons to antagonize various neurodegenerative mechanisms in AD, PD and AMD, and indirect effects of these compounds on peripheral disease-related risk factors.
Keywords: Alzheimer's disease, Parkinson's disease, Age-related macular degeneration, flavonoids, stilbenes, resveratrol, glycoconjugates, neuroinflammation, delocalization, dismutase
Current Pharmaceutical Design
Title: From Small to Big Molecules: How Do We Prevent and Delay the Progression of Age-Related Neurodegeneration?
Volume: 18 Issue: 1
Author(s): Yuen-Shan Ho, David Chun-Hei Poon, Tin-Fung Chan and Raymond Chuen-Chung Chang
Affiliation:
Keywords: Alzheimer's disease, Parkinson's disease, Age-related macular degeneration, flavonoids, stilbenes, resveratrol, glycoconjugates, neuroinflammation, delocalization, dismutase
Abstract: Age-related neurodegeneration in the brain and retina is complicated. It comprises a series of events encompassing different modes of degeneration in neurons, as well as inflammation mediated by glial cells. Systemic inflammation and risk factors can contribute to disease progression. Age-related conditions such as Alzheimers disease (AD), Parkinsons disease (PD) and Age-related Macular Degeneration (AMD) affect patients for 5 to 20 years and are highly associated with risk factors such as hyperhomocysteinæmia, hypercholesterolæmia, hypertension, and symptoms of mood disorder. The long duration of the degeneration and the wide array of systemic factors provide the opportunity for nutraceutical intervention to prevent or delay disease progression.
Small molecules such as phenolic compounds are candidates for neuroprotection because they have anti-oxidant activities and can modulate intracellular signaling pathways. Bigger entities such as oligosaccharides and polysaccharides have often been neglected because of their complex structure. However, certain big molecules can provide neuroprotective effects. They may also have a wide spectrum of action against risk factors.
In this review we use an integrative approach to the potential uses of nutraceutical products to prevent age-related neurodegeneration. These include direct effects of phenolic compounds and polysaccharides on neurons to antagonize various neurodegenerative mechanisms in AD, PD and AMD, and indirect effects of these compounds on peripheral disease-related risk factors.
Export Options
About this article
Cite this article as:
Ho Yuen-Shan, Chun-Hei Poon David, Chan Tin-Fung and Chuen-Chung Chang Raymond, From Small to Big Molecules: How Do We Prevent and Delay the Progression of Age-Related Neurodegeneration?, Current Pharmaceutical Design 2012; 18 (1) . https://dx.doi.org/10.2174/138161212798919039
DOI https://dx.doi.org/10.2174/138161212798919039 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strength and Weaknesses of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Possible Detection of Overlaps with Frailty Process
CNS & Neurological Disorders - Drug Targets Recent Research on Flavonoids and their Biomedical Applications
Current Medicinal Chemistry Acknowledgements to Reviewers:
Current Alzheimer Research Safety and Efficiency of Low Dose Intra-arterial Tirofiban in Mechanical Thrombectomy During Acute Ischemic Stroke
Current Neurovascular Research Glutamatergic Animal Models of Schizophrenia
Current Pharmaceutical Design The Efficacy of Psychological Therapies for Specific Phobias in Adults and Some Unanswered Questions
Current Psychiatry Reviews Urinary Metabolomics Reveals Alterations of Aromatic Amino Acid Metabolism of Alzheimer’s Disease in the Transgenic CRND8 Mice
Current Alzheimer Research Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model
CNS & Neurological Disorders - Drug Targets Classic β-Amyloid Deposits Cluster Around Large Diameter Blood Vessels Rather than Capillaries in Sporadic Alzheimers Disease
Current Neurovascular Research Available Treatment for Bipolar Disorder with Co-Occurring Substance and Alcohol Use Disorders: A Review
Current Psychiatry Reviews Bone Health in Children with Cerebral Palsy
Current Pediatric Reviews RNAi Applications in Therapy Development for Neurodegenerative Disease
Current Pharmaceutical Design Human Hepatocytes in Primary Culture: The Choice to Investigate Drug Metabolism in Man
Current Drug Metabolism Facial Pain Expression in Dementia: A Review of the Experimental and Clinical Evidence
Current Alzheimer Research The Realization of the Brain-Gut Interactions with Corticotropin-Releasing Factor and Glucocorticoids
Current Neuropharmacology Amidine-Based Bioactive Compounds for the Regulation of Arginine Metabolism
Mini-Reviews in Medicinal Chemistry The Molecular Targets of Antitumor 2-deoxycytidine Analogues
Current Drug Targets Role of Advanced Glycation End Products (AGEs) in Thrombogenic Abnormalities in Diabetes
Current Neurovascular Research Intracranial Venous Haemodynamics in Multiple Sclerosis
Current Neurovascular Research Antitumor Potential and Possible Targets of Phenothiazine-Related Compounds
Current Drug Targets